← Back to Search

Other

6,8-Bis(benzylthio)octanoic Acid for Acute Myeloid Leukemia

Phase 2

Waitlist Available

Led By Bayard Powell

Research Sponsored by Wake Forest University Health Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

Study Summary

This trial is testing a new cancer treatment combining 6,8-bis(benzylthio)octanoic acid, cytarabine, and mitoxantrone hydrochloride to see if it is more effective than current treatments for acute myeloid leukemia or granulocytic sarcoma.

Eligible Conditions

Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Feasibility of administering CPI-613 in combination with high dose cytarabine and mitoxantrone during induction, consolidation and maintenance therapies, defined as percentage of patients eligible for maintenance therapy who complete at least 3 courses

Secondary outcome measures

Frequency of toxicities experienced by the participants, graded using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0

Overall survival

Response rate (CR and CRi), assessed by standard criteria for AML

Other outcome measures

Complete response

Early mortality (death within 60 days of beginning of treatment) to the observed rates in a historical cohort of subjects

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)Experimental Treatment4 Interventions

See Detailed Description

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Mitoxantrone Hydrochloride

2016

Completed Phase 3

~650

Hematopoietic Cell Transplantation

2006

Completed Phase 2

~360

6,8-Bis(benzylthio)octanoic Acid

2015

Completed Phase 2

~50

Cytarabine

2016

Completed Phase 3

~3310

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,646 Previous Clinical Trials

40,930,977 Total Patients Enrolled

Wake Forest University Health SciencesLead Sponsor

1,236 Previous Clinical Trials

1,002,874 Total Patients Enrolled

Bayard PowellPrincipal InvestigatorWake Forest University Health Sciences

2 Previous Clinical Trials

460 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment currently open for recruitment of participants?

"The records on clinicaltrials.gov confirm that this study is not accepting new patients right now; its inception date was September 1st, 2015 and the last update occurred August 2nd 2022. Even though recruitment has been paused for this particular medical trial, there are over 2000 other trials actively searching for participants currently."

Answered by AI

What is the maximum capacity of participants in this research project?

"This clinical trial is currently not accepting new participants. It was first uploaded on September 1st 2015, and the post has been edited most recently on August 2nd 2022. However, there are 1895 other trials searching for those with sarcoma as well as 260 studies that require 6,8-Bis(benzylthio)octanoic Acid volunteers."

Answered by AI

Could you please provide an overview of the research conducted on 6,8-Bis(benzylthio)octanoic Acid?

"At present, 260 clinical trials exploring 6,8-Bis(benzylthio)octanoic Acid are still running with 63 of them in their final phase. Most studies are taking place within New york City's borders but there is a total of 9920 sites across the US that administer this medication."

Answered by AI

What therapeutic purposes is 6,8-Bis(benzylthio)octanoic Acid usually prescribed for?

"6,8-Bis(benzylthio)octanoic Acid is often employed to treat hodgkins lymphoma. This chemical compound can also be used in the management of blast phase chronic myelocytic leukemia, multiple sclerosis and acute myelocytic leukaemia."

Answered by AI